Can analyses of electronic patient records be independently and externally validated? Study 2-the effect of β-adrenoceptor blocker therapy on cancer survival: a retrospective cohort study

被引:24
作者
Springate, David A. [1 ,2 ]
Ashcroft, Darren M. [3 ]
Kontopantelis, Evangelos [1 ,4 ]
Doran, Tim [5 ]
Ryan, Ronan [6 ]
Reeves, David [1 ,2 ]
机构
[1] Univ Manchester, Inst Populat, Ctr Primary Care, NIHR Sch Primary Care Res,Hlth, Manchester, Lancs, England
[2] Univ Manchester, Inst Populat Hlth, Ctr Biostat, Manchester, Lancs, England
[3] Univ Manchester, Manchester Pharm Sch, Ctr Pharmacoepidemiol & Drug Safety, Manchester, Lancs, England
[4] Univ Manchester, Inst Populat Hlth, Ctr Hlth Informat, Manchester, Lancs, England
[5] Univ York, Dept Hlth Sci, York YO10 5DD, N Yorkshire, England
[6] Univ Birmingham, Sch Hlth & Populat Sci, Primary Care Clin Sci, Edgbaston, England
关键词
PRACTICE RESEARCH DATABASE; BREAST-CANCER; RISK; UK; ANTIBACTERIALS; VACCINATION; INHIBITORS; STATINS; USAGE; LIFE;
D O I
10.1136/bmjopen-2014-007299
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Objectives: To conduct a fully independent, external validation of a research study based on one electronic health record database using a different database sampling from the same population. Design: Retrospective cohort analysis of beta-blocker therapy and all-cause mortality in patients with cancer. Setting: Two UK national primary care databases (PCDs): the Clinical Practice Research Datalink (CPRD) and Doctors' Independent Network (DIN). Participants: CPRD data for 11 302 patients with cancer compared with published results from DIN for 3462 patients; study period January 1997 to December 2006. Primary and secondary outcome measures: All-cause mortality: overall; by treatment subgroup (beta-blockers only, beta-blockers plus other blood pressure lowering medicines (BPLM), other BPLMs only); and by cancer site. Results: Using CPRD, beta-blocker use was not associated with mortality (HR= 1.03, 95% CI 0.93 to 1.14, vs patients prescribed other BPLMs only), but DIN beta-blocker users had significantly higher mortality (HR= 1.18, 95% CI 1.04 to 1.33). However, these HRs were not statistically different (p=0.063), but did differ for patients on beta-blockers alone (CPRD=0.94, 95% CI 0.82 to 1.07; DIN=1.37, 95% CI 1.16 to 1.61; p<0.001). Results for individual cancer sites differed by study, but only significantly for prostate and pancreas cancers. Results were robust under sensitivity analyses, but we could not be certain that mortality was identically defined in both databases. Conclusions: We found a complex pattern of similarities and differences between databases. Overall treatment effect estimates were not statistically different, adding to a growing body of evidence that different UK PCDs produce comparable effect estimates. However, individually the two studies lead to different conclusions regarding the safety of beta-blockers and some subgroup effects differed significantly. Single studies using even internally well-validated databases do not guarantee generalisable results, especially for subgroups, and confirmatory studies using at least one other independent data source are strongly recommended.
引用
收藏
页数:11
相关论文
共 37 条
[1]   A collaborative approach to investigating the risk of thrombocytopenic purpura after measles-mumps-rubella vaccination in England and Denmark [J].
Andrews, Nick ;
Stowe, Julia ;
Miller, Elizabeth ;
Svanstrom, Henrik ;
Johansen, Kari ;
Bonhoeffer, Jan ;
Hviid, Anders .
VACCINE, 2012, 30 (19) :3042-3046
[2]  
[Anonymous], BMJ
[3]  
[Anonymous], BRIT J GEN PRACT
[4]  
[Anonymous], ANN ONCOL
[5]   Beta-adrenergic blocking drugs in breast cancer: a perspective review [J].
Barron, Thomas I. ;
Sharp, Linda ;
Visvanathan, Kala .
THERAPEUTIC ADVANCES IN MEDICAL ONCOLOGY, 2012, 4 (03) :113-125
[6]   Characteristics of study design and elements that may contribute to the success of electronic safety monitoring systems [J].
Bell, Carlos ;
Chakravarty, Aloka ;
Gruber, Susan ;
Heckbert, Susan R. ;
Levenson, Mark ;
Martin, David ;
Nelson, Jennifer C. ;
Pinheiro, Simone ;
Psaty, Bruce M. ;
Reich, Christian G. ;
Schneeweiss, Sebastian ;
Shoaibi, Azadeh ;
Toh, Sengwee ;
Walker, Alexander M. .
PHARMACOEPIDEMIOLOGY AND DRUG SAFETY, 2014, 23 (11) :1223-1225
[7]   Vaccinations, infections and antibacterials in the first grass pollen season of life and risk of later hayfever [J].
Bremner, S. A. ;
Carey, I. M. ;
DeWilde, S. ;
Richards, N. ;
Maier, W. C. ;
Hilton, S. R. ;
Strachan, D. P. ;
Cook, D. G. .
CLINICAL AND EXPERIMENTAL ALLERGY, 2007, 37 (04) :512-517
[8]   Early-life exposure to antibacterials and the subsequent development of hayfever in childhood in the UK: case-control studies using the General Practice Research Database and the Doctors' Independent Network [J].
Bremner, SA ;
Carey, IM ;
DeWilde, S ;
Richards, N ;
Maier, WC ;
Hilton, SR ;
Strachan, DP ;
Cook, DG .
CLINICAL AND EXPERIMENTAL ALLERGY, 2003, 33 (11) :1518-1525
[9]   Beta-blocker usage and prostate cancer survival: A nested case-control study in the UK Clinical Practice Research Datalink cohort [J].
Cardwell, Chris R. ;
Coleman, Helen G. ;
Murray, Liam J. ;
O'Sullivan, Joe M. ;
Powe, Des G. .
CANCER EPIDEMIOLOGY, 2014, 38 (03) :279-285
[10]   Beta-blocker usage and breast cancer survival: a nested case-control study within a UK Clinical Practice Research Datalink cohort [J].
Cardwell, Chris R. ;
Coleman, Helen G. ;
Murray, Liam J. ;
Entschladen, Frank ;
Powe, Des G. .
INTERNATIONAL JOURNAL OF EPIDEMIOLOGY, 2013, 42 (06) :1852-1861